French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Monday announced positive results from the Phase 2 CoTikiS study of Lusvertikimab (OSE-127), an anti-IL7R monoclonal antibody, for the treatment of ulcerative colitis (UC).
Lusvertikimab met the primary endpoint, demonstrating significant improvement in the Modified Mayo Score at both doses tested. The drug also showed positive results on key secondary endpoints, including clinical and endoscopic remission.
The drug was well-tolerated with a favourable safety profile during both the induction and extension periods.
These results position Lusvertikimab as a potential first-in-class interleukin-7 antagonist for the treatment of autoimmune and inflammatory diseases.
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Boehringer Ingelheim discontinues development of NYP2 agonist